Clinical Trials on Constipation in Finland

Total 44 results

Kuopio University Hospital

Completed

The Function of Gastrointestinal Tract During Pregnancy (umpiraskaus)

Constipation

Finland
Orion Corporation, Orion Pharma

Completed

Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation (PEGorion)

Constipation

Finland
Kuopio University Hospital

Completed

Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery (oksineukir)

Constipation

Finland
Kuopio University Hospital
Admescope Ltd

Active, not recruiting

Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section (oksisektio)

Pain, Postoperative | Constipation

Finland
Kyowa Kirin Pharmaceutical Development Ltd
Apices Soluciones S.L.

Completed

Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. (NACASY)

Opioid Induced Constipation

Netherlands, Sweden, Finland, Denmark, Spain, France, Germany, Greece, Italy, United Kingdom
Braintree Laboratories

Completed

A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults

Constipation

United States
Sucampo Pharma Americas, LLC
Takeda

Completed

Lubiprostone for Children With Constipation

Constipation - Functional

United States, United Kingdom, Netherlands, Poland, Belgium, France, Canada
Sucampo Pharma Americas, LLC
Sucampo AG

Completed

Lubiprostone in Children With Functional Constipation

Constipation - Functional

United States, United Kingdom, Canada, Netherlands, Poland, Belgium, France
SK Life Science, Inc.

Completed

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Chronic Constipation

United States, Canada
Mundipharma Research GmbH & Co KG

Completed

Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain (HMX3501)

Constipation

Romania, Switzerland, Israel, Belgium, Germany, Australia, Austria, Czech Republic, Denmark, Finland, France, Netherlands, Poland, United Kingdom
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Functional Constipation in Children Ages 6-17 Years

United States, Canada
Bausch Health Americas, Inc.
Parexel

Completed

The Plecanatide Chronic Idiopathic Constipation (CIC) Study

Chronic Idiopathic Constipation

United States
AbbVie
Ironwood Pharmaceuticals, Inc.

Enrolling by invitation

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Canada, Israel, Netherlands
Bausch Health Americas, Inc.
Syneos Health

Completed

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation

United States, Canada
AstraZeneca

Completed

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

United States, Australia, Slovakia, Germany
AstraZeneca

Completed

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

United States, Germany, Australia, Slovakia
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Southwest Oncology Group
National Cancer Institute (NCI); Agency for Healthcare Research and Quality...

Completed

S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction

Unspecified Adult Solid Tumor, Protocol Specific | Constipation, Impaction, and Bowel Obstruction

United States, Canada, Colombia, Peru, Mexico
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Opioid-Induced Constipation

United States
Bausch Health Americas, Inc.

Completed

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Mundipharma Research GmbH & Co KG

Completed

OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

Chronic Osteoarthritis

Spain, Belgium, Finland, Czechia, Germany, Hungary
Bausch Health Americas, Inc.
Pfizer

Completed

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

Constipation

Canada, United States, Colombia, Korea, Republic of, Australia, Spain
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)

Irritable Bowel Syndrome Characterized by Constipation

United States
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Cancer | Bowel Dysfunction

United States, France, Canada, Finland, Spain, Pakistan, Poland, Hong Kong, United Kingdom, Peru, New Zealand, Portugal, Russian Federation
Sucampo Pharma Americas, LLC
Sucampo Pharmaceuticals, Inc.

Completed

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone (OPAL)

Opioid-Induced Bowel Dysfunction

United States, Canada
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Constipation | Bowel Dysfunction

United States, Taiwan, Australia, Canada, Hungary, Spain, Finland, United Kingdom, Hong Kong, Sweden, Austria, Denmark, Poland, Netherlands, New Zealand, Ireland, Switzerland
AstraZeneca

Terminated

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

Opioid-Induced Constipation

Croatia, United States, Bulgaria, United Kingdom, Poland, Romania, Belgium, Puerto Rico, Slovakia, Australia, South Africa, Czech Republic, Germany, Spain
Purdue Pharma LP

Completed

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Constipation | Bowel Dysfunction

United States, Germany, Estonia, Finland, United Kingdom, Canada, Austria, Denmark, Poland, Ireland
Purdue Pharma LP

Completed

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Low Back Pain

United States, Poland, Czech Republic, Italy
Sucampo Pharma Americas, LLC
Sucampo Pharmaceuticals, Inc.

Completed

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Opioid-induced Bowel Dysfunction

United States, Czechia, Germany, Belgium, Poland, Sweden, United Kingdom
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Constipation | Bowel Dysfunction

United States, Netherlands, Spain, Taiwan, Peru, Philippines, France, United Kingdom, Canada, Czechia, Finland, Korea, Republic of, Hong Kong, Pakistan, Thailand, Italy, Argentina, Poland, Hungary, Germany, Russian Federation, South... and more
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Constipation | Bowel Dysfunction

United States, Australia, Canada, Hungary, Netherlands, Spain, Sweden, France, New Zealand, Norway, South Africa, Switzerland
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Nausea | Constipation | Diarrhea | Purpura | Lymphadenopathy | Gastrointestinal Hemorrhage | Hepatomegaly | Primary Systemic Amyloidosis | Amorphous, Eosinophilic, and Acellular Deposit | Early Satiety | Macroglossia | Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis

United States

Clinical Trials on Constipation in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations